Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137) announced the issuance of a total of 159,900 shares due to the grant of restricted stock units from September 1 to September 17, 2025 [1] Summary by Relevant Categories - **Company Actions** - The company will issue a total of 159,900 shares as part of the restricted stock units granted [1] - **Timeline** - The issuance will occur between September 1 and September 17, 2025 [1]

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance of a total of 159,900 shares due to the allocation of restricted stock units from September 1 to September 17, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 騰盛博藥生物科技有限公司 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 2). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | 86,430 0.012 % HKD 0 | | --- | --- | --- | | 而發行新股或轉讓庫存股份 - 涉及新股 | | | | 根據於2021年6月22日採納的本公司首次公開發售後股份獎勵計劃， | | | | 歸屬授出的受限制股份單位而發行及配發予本公司僱員之股份。 | | | | 變動日期 2025年9月2日 | | | | 3). 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | | 49,550 0.0069 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 騰盛博藥生物科技有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02137 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.000005 | USD | | 6,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.000005 | USD ...

Announcement Background and Purpose Brii Biosciences Limited issues a supplemental announcement to provide additional details on the use of net proceeds from its global offering in the 2024 annual report, specifically regarding unutilized funds carried forward to January 1, 2024 - This announcement supplements the 2024 annual report, focusing on the use of net proceeds from the global offering[2](index=2&type=chunk) - It highlights the specific amount of **unutilized net proceeds** as of December 31, 2023, carried forward to January 1, 2024[2](index=2&type=chunk) [Details on Use of Net Proceeds from Global Offering](index=2&type=section&id=%E5%85%A8%E7%90%83%E7%99%BC%E5%94%AE%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%94%A8%E9%80%94%E8%A9%B3%E6%83%85) This section details the original and revised uses of the company's global offering net proceeds, utilized amounts as of December 31, 2024, and unutilized funds carried forward from December 31, 2023, to January 1, 2024, covering various R&D projects and working capital - As of December 31, 2024, a total of **HKD 25.256 million** of net proceeds from the global offering has been utilized (**HKD 9.941 million** from Group 1 allocation and **HKD 15.315 million** from Group 2 allocation)[3](index=3&type=chunk)[4](index=4&type=chunk) - As of December 31, 2024, **HKD 1.760 million** remains unutilized, primarily allocated to Group 1 R&D projects and working capital[3](index=3&type=chunk) [Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024](index=2&type=section&id=2.1%20%E6%88%AA%E8%87%B32023%E5%B9%B412%E6%9C%8831%E6%97%A5%E6%9C%AA%E5%8B%95%E7%94%A8%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%B5%90%E8%BD%89%E8%87%B32024%E5%B9%B41%E6%9C%881%E6%97%A5) As of December 31, 2023, **HKD 14.666 million** of the company's global offering net proceeds remained unutilized and was carried forward to January 1, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital Unutilized Net Proceeds as of December 31, 2023, Carried Forward to January 1, 2024 (Million HKD) | Project | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Unutilized Net Proceeds (Million HKD) | Percentage of Original Total Net Proceeds (%) | | :------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------- | | BRII-179 | 11.959 | 11.959 | 7.848 | 46% | | BRII-732 | 1.307 | 1.307 | 1.400 | 5% | | BRII-835 | 0.261 | 0.261 | 1.307 | 5% | | BRII-877 | 14.666 | 14.666 | 5.141 | 56% | | BRII-753 | 1.400 | 1.400 | 1.400 | 6% | | Other R&D Projects | 1.517 | 1.517 | 1.517 | 32% | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 11.959 | 1% | | **Total** | **26.138** | **26.138** | **14.666** | **100%** | [Overview of Net Proceeds Utilization as of December 31, 2024](index=2&type=section&id=2.2%20%E6%88%AA%E8%87%B32024%E5%B9%B412%E6%9C%8831%E6%97%A5%E6%89%80%E5%BE%97%E6%AC%BE%E9%A0%AD%E6%B7%A8%E9%A1%8D%E7%94%A8%E9%80%94%E6%A6%82%E8%A7%88) As of December 31, 2024, a total of **HKD 25.256 million** from the global offering net proceeds has been utilized (**HKD 9.941 million** from Group 1 and **HKD 15.315 million** from Group 2), with **HKD 1.760 million** remaining unutilized, primarily in Group 1 R&D projects and working capital [Utilization of Group 1 Allocated Funds](index=2&type=section&id=2.2.1%20%E7%AC%AC%E4%B8%80%E7%BB%84%E5%88%86%E9%85%8D%E7%9A%84%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5) Of the **HKD 26.138 million** net proceeds from the global offering allocated to Group 1, **HKD 9.941 million** was utilized as of December 31, 2024, primarily for R&D projects like BRII-179, BRII-877, and working capital, with **HKD 1.760 million** remaining unutilized Utilization of Group 1 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-179 | 11.959 | 11.959 | 6.818 | 1.555 | | BRII-732 | 1.307 | 1.307 | 1.517 | 1.307 | | BRII-835 | 0.261 | 0.261 | 0.243 | 0.261 | | BRII-877 | 14.666 | 14.666 | 3.123 | 1.825 | | BRII-753 | 1.400 | 1.400 | 1.825 | 0.053 | | Other R&D Projects | 1.517 | 1.517 | 4.948 | 3.380 | | Working Capital and Other General Corporate Purposes | 8.373 | 8.373 | 0.296 | 0.261 | | **Total** | **26.138** | **26.138** | **9.941** | **1.760** | [Utilization of Group 2 Allocated Funds](index=3&type=section&id=2.2.2%20%E7%AC%AC%E4%BA%8C%E7%BB%84%E5%88%86%E9%85%8D%E7%9A%84%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5) The **HKD 15.315 million** net proceeds from the global offering allocated to Group 2 were fully utilized as of December 31, 2024, primarily for R&D projects like BRII-297, BRII-636, and working capital, with no unutilized balance Utilization of Group 2 Allocated Funds as of December 31, 2024 (Million HKD) | Project/Purpose | Original Proposed Use (Million HKD) | Revised Proposed Use (Million HKD) | Funds Utilized (Million HKD) | Unutilized Net Proceeds as of 2024-12-31 (Million HKD) | | :--------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :----------------------------------------------------------------- | | BRII-297 | 0.675 | 0.675 | 0.675 | 0 | | BRII-636 | 0.590 | 0.590 | 0.590 | 0 | | BRII-672 | 0.085 | 0.085 | 0.085 | 0 | | BRII-296 | 2.746 | 2.746 | 2.746 | 0 | | BRII-693 | 3.920 | 3.920 | 3.920 | 0 | | Other R&D Projects | 2.614 | 2.614 | 2.614 | 0 | | Working Capital and Other General Corporate Purposes | 26.138 | 26.138 | 26.138 | 0 | | **Total** | **15.315** | **15.315** | **15.315** | **0** | [Other Information and Board Statement](index=4&type=section&id=%E5%85%B6%E4%BB%96%E4%BF%A1%E6%81%AF%E4%B8%8E%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%A3%B0%E6%98%8E) The additional information disclosed in this supplemental announcement does not affect other content in the 2024 annual report, with all other information remaining unchanged, and includes details on the company's board members - The additional information in this supplemental announcement does not affect other information in the 2024 annual report[5](index=5&type=chunk) - Board members include Executive Directors Dr Zhi Hong and Dr Li Ankang, along with several Independent Non-executive Directors[6](index=6&type=chunk)

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance and allocation of 130,800 shares to employees as part of its restricted share unit plan adopted on June 22, 2021 [1]

Group 1 - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the issuance and allocation of 130,800 shares to employees as part of its restricted share unit plan adopted on June 22, 2021 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02137 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份總數 | | | | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | | 於下列日期開始時的結存(註1) | | 2025年7月31日 | | 719,377,383 | | 12,723,500 ...

Financial Data and Key Metrics Changes - As of June 30, 2025, the company's bank deposits and cash and cash equivalents were $2,075.3 million, representing a decrease of $338.1 million or 14% compared to $2,413.4 million at the end of 2024 [26] - Other income for the first half of the year was $28.1 million, a decrease of $42.8 million or 60.4% compared to $70.9 million for the same period in 2024 [27] - Research and development expenses for the first half of the year declined by 7.3% to $117 million from $126.2 million in 2024 [28] - Administrative expenses were $58.2 million in the first half of the year, declining 26% compared to $78.6 million in 2024 [28] Business Line Data and Key Metrics Changes - The HBV functional cure strategy is built on three differentiated assets: BRE-179, elapsirin, and tolivibart, each targeting distinct mechanisms of HBV pathogenesis [7] - The ongoing clinical programs have collectively been studied in more than 1,600 patients, with three fully enrolled Phase IIb combination studies [9] - In cohort four of the INSURE study, 61% of BRE-179 responders achieved HB surface antigen loss at week 48, compared to about 10% of non-responders [10] Market Data and Key Metrics Changes - The company out-licensed the Greater China rights of Xarelin mixing to ensure efficient progress of non-core programs without diverting focus from HBV [5] - The company is seeking strategic partnerships to develop other assets in its pipeline, including long-acting HBV candidates [6] Company Strategy and Development Direction - The company is focused on advancing its core HBV functional cure program through multiple Phase 2b studies and is shaping its late-stage development strategy based on emerging data [4] - The company aims to achieve a higher rate of functional cure through a multimodal parallel approach, which is critical to solving the complexity of HBV cure [24] - The company plans to report 24-week follow-up data from cohort four of the INSURE study in 2025, with end-of-treatment data from the ENRICH and ENHANCE studies expected in 2026 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the development of new treatment modalities for HBV and the company's focus on providing a curative regimen [48] - The company believes that the recent launch of a new reporting system by the China CDC will improve the diagnostic rate of HBV, potentially increasing treatment demand [44] Other Important Information - The company has maintained a strong cash position with sufficient funds to support operations through 2028 [26] - The company is committed to pairing internal innovation with external collaboration to drive sustainable growth and broaden patient access to meaningful treatment options [28] Q&A Session Summary Question: Given the encouraging 61% seroclearance rate in BRE-179 responders from INSURE study cohort number four, how is the company thinking about patient enrichment strategy moving forward? - Management acknowledged the potential of BRE-179 to categorize chronic HBV patients into immune responsive and non-responsive groups and is exploring biomarker-driven approaches for Phase III trials [32][34] Question: What is the company's view on the competitive landscape considering recent phase three trials initiated by OSPER Bio? - Management expressed excitement about new treatment modalities for HBV and noted the importance of long-term follow-up data from competitors to evaluate the evolving landscape [38][40] Question: How does the company assess the potential impact of the new reporting system launched by the China CDC on treatment demands? - Management views the new reporting system as a positive development that could increase diagnosis rates and improve disease awareness, ultimately benefiting patients [44][46]

Financial Performance - The company reported a total other income of RMB 28.1 million for the first half of 2025, representing a year-on-year decrease of 60.4% [1] - Research and development expenses amounted to RMB 117 million, down 7.3% year-on-year [1] - The net loss for the period was approximately RMB 149 million, a reduction of 47.5% compared to the previous year [1] - Loss attributable to shareholders was about RMB 148 million, reflecting a decrease of 47.22% year-on-year [1] - The reduction in losses was primarily due to a decrease in other losses related to fair value changes of equity investments by RMB 115.5 million, a decrease in impairment losses under expected credit loss model by RMB 33 million, and a reduction in operating expenses [1] Strategic Developments - The company achieved a significant milestone by granting an external license for soralimixin (BRII-693), a new antibiotic for treating severe MDR/XDR Gram-negative bacterial infections [2] - In July 2025, the company announced a collaboration with Health元 Group to grant rights for research, development, and commercialization of soralimixin (BRII-693) in the Greater China region [2] - This partnership allows the company to focus its internal resources on core HBV projects while advancing the regional development and commercialization of soralimixin (BRII-693) [2] - The collaboration is expected to accelerate access to urgently needed anti-infection treatments in Greater China, and clinical data generated during the development process may support further development of soralimixin (BRII-693) in other regions [2]